miR-381失调在小儿急性髓系白血病中的临床意义

Clinical significance of dysregulation of miR-381 in pediatric acute myeloid leukemia.

作者信息

Zhang Piqiang, Sun Deyun, Sun Xuemei, Li Hongjuan

机构信息

Department of Pediatrics, Linyi People Hospital, No. 27, East Jiefang Road, Linyi, 276003, Shandong, China.

出版信息

Eur J Med Res. 2020 Sep 16;25(1):42. doi: 10.1186/s40001-020-00442-1.

DOI:10.1186/s40001-020-00442-1

PMID:32938467

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7493963/

Abstract

BACKGROUND

microRNA-381 is dysregulated in a variety of cancers. However, its clinical significance in pediatric acute myeloid leukemia (AML) is still unclear. The purpose of this study was to detect the expression level of miR-381 in pediatric AML patients and to explore its potential clinical significance.

METHODS

The levels of miR-381 in bone marrow and serum of 102 pediatric AML patients were measured by quantitative real-time polymorperase chain reaction (qRT-PCR). The diagnostic value of serum miR-381 in pediatric AML patients was evaluated by the receiver operating characteristic (ROC) curve. A Chi square test was used to analyze the relationship between serum miR-381 and the clinical characteristics of patients. Cox regression analysis and Kaplan-Meier evaluated the prognostic value of serum miR-381 in patients. Finally, the proliferation of the cells was analyzed by the CCK-8 assay.

RESULTS

Compared with healthy controls, the levels of miR-381 in serum and bone marrow of pediatric AML patients were significantly decreased (P < 0.001). ROC curve showed that miR-381 could distinguish pediatric AML cases from normal controls. At the same time, the downregulation of miR-381 was associated with M7 in the French-American-British (FAB) classifications and unfavorable cytogenetic risks (P < 0.05). Low serum miR-381 levels were associated with poor overall survival of pediatric AML (log-rank test, P = 0.011) and poor relapse-free survival (log-rank test, P = 0.004). Cox regression analysis confirmed that reduced serum miR-381 was an independent predictor of poor prognosis in AML (HR = 3.794, 95% CI 1.3633-10.559, P = 0.011). In addition, low expression of miR-381 significantly reduced the proliferation of cells (P < 0.05).

CONCLUSION

All experimental results confirm that miR-381 has reduced bone marrow and serum expression in pediatric AML, and low levels of serum miR-381 have certain diagnostic and prognostic value in pediatric AML and may be a potential therapeutic target for AML.

摘要

背景

微小RNA-381在多种癌症中表达失调。然而，其在儿童急性髓系白血病（AML）中的临床意义仍不清楚。本研究旨在检测儿童AML患者中miR-381的表达水平，并探讨其潜在的临床意义。

方法

采用定量实时聚合酶链反应（qRT-PCR）检测102例儿童AML患者骨髓和血清中miR-381的水平。通过受试者工作特征（ROC）曲线评估血清miR-381对儿童AML患者的诊断价值。采用卡方检验分析血清miR-381与患者临床特征之间的关系。Cox回归分析和Kaplan-Meier评估血清miR-381对患者的预后价值。最后，通过CCK-8法分析细胞的增殖情况。

结果

与健康对照相比，儿童AML患者血清和骨髓中miR-381水平显著降低（P < 0.001）。ROC曲线显示，miR-381可区分儿童AML病例与正常对照。同时，miR-381的下调与法国-美国-英国（FAB）分类中的M7以及不良细胞遗传学风险相关（P < 0.05）。血清miR-381水平低与儿童AML患者的总生存期差（对数秩检验，P = 0.011）和无复发生存期差（对数秩检验，P = 0.004）相关。Cox回归分析证实，血清miR-381降低是AML预后不良的独立预测因素（HR = 3.794，95%CI 1.3633 - 10.559，P = 0.011）。此外，miR-381低表达显著降低细胞增殖（P < 0.05）。